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A disease is considered rare when it has a prevalence in 
the general population below a given threshold, i.e., when few 
people are affected. The European Union defines this threshold 
to 0.05% of the population, i.e. 1:2000 inhabitants, and Italy ad-
heres to this definition. The definition “rare”, however, rather 
than to simply stigmatize the epidemiology of certain diseases, 
has long labeled disorders considered to represent an insurmount-
able frontier to the possibility to find a therapy for every human 
disease, despite the detailed knowledge on their pathogenesis 
and etiology. In the course of the years devoted to the research of 
therapies for rare disease, one main factor of frustration has been 
the finding that promising results obtained in “in vitro models” 
by traditional biochemistry and pharmacology methodologies 
were usually not replicable in human beings. The pharmaceuti-
cal industry has therefore traditionally manifested scarce interest 
in rare diseases. The inability to provide therapy to patients af-
fected by a rare disease has limited the interest of practitioners on 
this topic. Rare disease are, therefore, generally under-diagnosed 
and technologies and expertise necessary to diagnose them are 
only available in a few university and hospital specialized cent-
ers even in the most advanced nations. Treatment is, therefore, 
restricted to treat the symptoms, in the large majority of patients 
with rare diseases. A turning point in a positive direction to the 
efforts of researchers came by applying molecular biology and 
recombinant DNA technologies to drugs development. This has 
rendered possible to produce species-specific molecules capable 
to effectively replace “in vivo” native molecules not correctly 
working in specific diseases. One relevant result of the applica-
tion of these advanced methodologies has been represented by 
the recombinant alpha-glucosidase (alglucosidase alpha – My-
ozyme) that became available for enzyme replacement therapy 
(ERT) of Pompe disease in the year 2000 (1). 
Pompe disease (synonym: “acid maltase deficiency”) having 
an estimated frequency varying from one in 40000 in Caucasians 
to one in 146000 in Australian populations is a rare pan-ethnic 
autosomal recessive genetic disorder. It is a lysosomal storage 
disease classified as type II glycogenosis being caused by muta-
tions in the gene encoding the acid α-glucosidase (GAA), locat-
ed on 17q25.2-q25.3. Acidic α-glucosidase (α-GA) is a glyco-
protein enzyme which degrades glycogen to glucose within the 
lysosomes. Shortage of α-GA activity in Pompe disease ham-
pers the lysosomal degradation of glycogen that progressively 
accumulates inside the lysosome. These latter become unusu-
ally large and fuse to form wide spaces that eventually occupy 
a substantial part of the cellular volume and are recognizable as 
intracytoplasmic glycogen storing vacuoles at microscopy. The 
ensuing cellular pathology predominantly affects muscle fibers 
displacing  their  myofibrils  and  ultimately  leading  to  skeletal 
muscle weakness, but also other tissues (particularly cardiac and 
smooth muscle cells) and organs show vacuolation of their cells 
cytoplasm. The resulting clinical spectrum ranges from the clas-
sical infantile form presenting soon after birth, that is character-
ized by hypertrophic cardiomyopathy and marked muscle weak-
ness, and leads to death usually before the first year of age, to 
a milder form characterized by gradually progressing miopathy 
and respiratory insufficiency with either juvenile or adult onset. 
These latter lead progressively to varying degrees of disability 
and are associated to reduced life expectancy on average. The 
different disease phenotypes correlates with the levels of residual 
α-GA activity in muscle; less than 3% of normal enzyme activity 
is found in severe infantile cases and residual levels ranging 3 - 
30% of normal are found in less severe late onset forms (2).
Several published studies support the effectiveness of ERT 
with alglucosidase alpha in inducing significant improvement 
of motor and heart functions and dramatic extension of survival 
time in infants with the classic form of Pompe disease (3). Al-
though the effects of long-term therapy are still unknown and a 
marked variability in the individual response to the drug is un-
deniable, these encouraging data make advisable starting ERT 
with alglucosidase alpha as soon as possible both in affected 
infants and symptomatic adults. Follow-up of patients with late-
onset Pompe disease should be continued for several years to 
assess the full efficacy of treatment. In view of the high cost 
of ERT, it is also advisable to perform a careful long term ob-
servation of untreated pre- and mildly-symptomatic patients to 
identify, if possible, markers that allow prediction of the clini-
cal evolution. This in order to distinguish patients needing ERT 
treatment from patients who can maintain autonomy and a good 
quality of life being supported from exercise therapy, diet, and 
assisted ventilation when adequate. 
The diagnosis of the classic infantile form of Pompe dis-
ease is made, usually, early and relatively easily because, due 
to the marked severity of the symptoms of the disease yet at 
it onset, the little patients are immediately admitted to pediat-
ric intensive care centers where physicians are well trained to 
recognize the disease. Conversely, the diagnosis of late-onset 
forms is complicated by the rarity of the condition and the heter-
ogeneity of the clinical manifestations, which vary with respect 
to organ involvement, age at onset, and severity. Symptoms are 
often unspecific especially at onset and they may remain mild 
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even for decades so that neither the patient nor the doctor con-
sider to deepen diagnostic procedures. 
The diagnosis of Pompe disease requires the knowledge of 
the clinical presentation which is highly variable with respect 
to age at onset, disease severity, organ involvement, and clini-
cal course. This wide clinical variability results from genetic 
heterogeneity, and more than 200 different mutations of the 
GAA gene have been reported. Clinical evaluation of suspected 
Pompe patients should be followed by laboratory evaluation, in-
cluding blood tests creatine kinase, aspartate aminotranferase, 
alanine aminotransferase, lactate dehydrogenase), EMG, senso-
ry-motor-nerve conduction studies, muscle biopsy (histological, 
histochemical and biochemical studies), cardiological and res-
piratory assessments, and skeletal muscle Magnetic Resonance 
Imaging studies. Finally, the diagnosis must be definitely con-
firmed by evaluation of α-GA enzyme activity in skeletal muscle 
tissues or skin fibroblasts and molecular analysis of GAA gene. 
Management of Pompe disease requires a multidiscipli-
nary approach given by a team which should include several 
specialists such as neonatologists, pediatricians, neuromuscular 
specialists,  neurologists,  cardiologists,  pulmonologists,  bio-
chemical geneticists, genetic counselors, intensivists, physical 
therapists, respiratory therapists, metabolic dieticians, orthope-
dists,  radiologists,  occupational  therapists,  otolaryngologists, 
audiologists, speech therapists, and psychologists, who will be 
capable of addressing the different manifestations of the condi-
tion. It is important to consider that both the patients and their 
families need psychological support to tolerate the psycho-so-
cial distress related to living with a chronic illness and, mostly, 
to deal with the personal, emotional and relational consequenc-
es arising from the awareness that the disease of the family is 
a hereditary one. Fundamental in Pompe disease is also, as in 
other chronically disabling diseases that affect children, adoles-
cent and adults, to train healthy family members and caregivers 
to help the patients in the execution of their daily activities in the 
better way with respect to the individual residual abilities. 
In October 2006, a group of leading Italian Pompe disease 
experts held a round table meeting to review, from a multidis-
ciplinary point of view, new development in glicogenosis type 
II. Best practice and unmet needs regarding the recognition, 
evaluation, and surveillance of disease associated morbidities, 
as well as therapeutic strategies, enzyme replacement therapy 
with alglucosidase alpha, and other adjunctive therapies, to op-
timize patient outcomes have been identified. One main conclu-
sion of this meeting was that because of the complexity of the 
clinical picture of these patients it is warranted that primary care 
providers and other specialists who might be involved in their 
care become aware of the disease (4). Following this meeting 
the Italian Study Group for Glycogenosis has been constituted 
within the Italian Association of Myology, with the aim between 
others to promote the awareness of Pompe disease between the 
specialists working at University and Hospital medical Cent-
ers and the practitioners in all regions in Italy. The constitution 
of territorial networks of medical specialists, nurses, caregivers 
and Pompe patients Family associations is also promoted.
Epidemiological assessments indicates that in south Italy 
the late-onset forms of Pompe disease are largely under-diag-
nosed. In fact, with an estimated frequency of one in 56000 in 
Caucasian populations late-onset cases should be about 100 in 
the 6x103 inhabitants of the Campania, but after a recognition at 
all the Centers specialized for neuromuscular diseases of this re-
gion, in June 2011, at the time of the present Meeting, less than 
10 genetically proofed patients result to be followed up. 
With these premises the team of neuromuscular disorders 
specialists at the Department of Neurology directed by profes-
sor Giuseppe Di Iorio, together with the team of Cardiomyol-
ogy  and  Medical  Genetics,  directed  by  professor  Giovanni 
Nigro and professor Luisa Politano of the Second University 
of Naples, have organized the meeting ”A network for Pompe 
disease treatment. Genetic Myopathy of children and adults” 
held in Naples, Italy, on June the 13th, 2011. Specific aims of 
the meeting were:
•	 to	perform	a	comprehensive	review	from	a	multidisciplinary	
point of view on basic knowledge and new developments on 
clinic, diagnosis and management of Pompe disease;
•	 to	 discuss	 personal	 experiences	 with	 the	 management	 of	
Pompe  disease  between  experts  in  clinical  and  laboratory 
diagnosis,  treatment,  and  management,  including,  cardiac, 
respiratory, gastrointestinal/nutritional, muscoloskeletal, neu-
rological, supportive and rehabilitative care, anaesthesiology, 
general medicine, psychosocial, issues.
The meeting addressed to University and Hospital doctors, 
practitioners and doctors in training in all branches potentially 
involved in diagnosis, therapy and management of Pompe pa-
tients had more than 100 registered participants. 
The Meeting will benefit of the contributions of speak-
ers of international scientific level, such as Corrado Angelini, 
from the University of Padua, who first described along with 
Engel AG, variable levels of α-GA in muscle and leukocytes of 
patients with Pompe disease, Antonio Toscano, from the Uni-
versity of Messina, Coordinator of the Italian Group for the 
Study of Glycogenosis, who will report on the Italian guide-
lines and the activities of the Italian centers for the treatment 
of Pompe disease, Generoso Andria, from the University of 
Naples, Coordinator of the Reference Center for Rare Diseas-
es of the Campania region, who first treated with alglucosidase 
alpha an Italian patient with classic infantile Pompe disease 
and will speake about the role of the pediatrician in the infan-
tile form of Pompe disease. Furthermore, all important topics 
in clinics, diagnosis and treatment of Pompe disease, such as 
the therapeutic strategies alternatives to ERT, will be discussed 
by several experts from the universities and some hospitals of 
Naples and the Campania region. 
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